Download PDF
Semin Thromb Hemost 2021; 47(01): 011-017
DOI: 10.1055/s-0040-1714398
Review Article

Anabolic–Androgenic Steroid Abuse Impairs Fibrin Clot Lysis

Johannes Jakobsen Sidelmann
1   Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark
2   Unit for Thrombosis Research, Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark
,
Jørgen Brodersen Gram
1   Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark
2   Unit for Thrombosis Research, Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark
,
Jon J. Rasmussen
3   Department of Endocrinology and Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark
4   Department of Internal Medicine, Holbæk Hospital, Region Zealand, Denmark
,
Caroline Kistorp
3   Department of Endocrinology and Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark
5   Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Abuse of anabolic–androgenic steroids (AASs) is suspected to increase the risk of cardiovascular disease (CVD) and cardiovascular mortality in otherwise healthy individuals. AAS abuse may increase the incidence of CVD by altering the hemostatic balance toward a procoagulant state. Studies on the effect of AAS abuse on the fibrinolytic system, however, have either demonstrated a profibrinolytic effect or no effect of AAS abuse, but the overall effect of AAS on fibrinolysis has not been addressed so far. This cross-sectional study investigated the effect of AAS on fibrin clot lysis, fibrin structure, and the hemostatic proteins, potentially affecting these measures in current and former AAS abusers and healthy age-matched controls. The study population consisted of 37 current and 33 former AAS abusers, along with 30 healthy age-matched controls. Fibrin clot lysis, fibrin structure properties, fibrinogen, coagulation factor XIII (FXIII) plasminogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined. Fibrin clot lysis was significantly reduced in participants abusing AAS compared with former abusers and controls (p < 0.001). Plasma fibrinogen, plasminogen, and plasmin inhibitor were significantly increased in current abusers (p < 0.05). No significant differences were observed with respect to measures of fibrin structure properties, PAI-1, and TAFI (p > 0.05). In conclusion, AAS abuse depresses fibrin clot lysis. This effect is not associated with alterations in fibrin structure but is rather caused by increased plasma concentrations of fibrinogen, FXIII, and plasmin inhibitor. These findings suggest that AAS abuse may be associated with increased thrombotic disease.

Keywords

anabolic–androgenic steroids - fibrinolysis - fibrin clot structure - coagulation


Publication History

Article published online:
05 October 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Pope Jr HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates. Am J Addict 2014; 23 (04) 371-377
    CrossrefPubMedGoogle Scholar
  • 2 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol 2014; 24 (05) 383-398
    CrossrefPubMedGoogle Scholar
  • 3 Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med 2012; 42 (02) 119-134
    CrossrefPubMedGoogle Scholar
  • 4 Baggish AL, Weiner RB, Kanayama G. et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation 2017; 135 (21) 1991-2002
    CrossrefPubMedGoogle Scholar
  • 5 La Gerche A, Brosnan MJ. Cardiovascular effects of performance-enhancing drugs. Circulation 2017; 135 (01) 89-99
    CrossrefPubMedGoogle Scholar
  • 6 Rasmussen JJ, Schou M, Madsen PL. et al. Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids. Am Heart J 2018; 203: 49-56
    CrossrefPubMedGoogle Scholar
  • 7 Lippi G, Banfi G. Doping and thrombosis in sports. Semin Thromb Hemost 2011; 37 (08) 918-928
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Thiblin I, Garmo H, Garle M. et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend 2015; 152: 87-92
    CrossrefPubMedGoogle Scholar
  • 9 Chang S, Rasmussen JJ, Frandsen MN. et al. Procoagulant state in current and former anabolic androgenic steroid abusers. Thromb Haemost 2018; 118 (04) 647-653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Chang S, Münster AB, Gram J, Sidelmann JJ. Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis. Semin Thromb Hemost 2018; 44 (08) 734-746
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?. Ann Med 2006; 38 (06) 378-388
    CrossrefPubMedGoogle Scholar
  • 12 Undas A, Ariëns RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31 (12) e88-e99
    CrossrefPubMedGoogle Scholar
  • 13 Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. Semin Thromb Hemost 2017; 43 (02) 178-184
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Rasmussen JJ, Selmer C, Østergren PB. et al. Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study. PLoS One 2016; 11 (08) e0161208
    CrossrefPubMedGoogle Scholar
  • 15 Rasmussen JJ, Schou M, Selmer C. et al. Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids. Clin Endocrinol (Oxf) 2017; 87 (03) 249-256
    CrossrefPubMedGoogle Scholar
  • 16 Rasmussen JJ, Schou M, Madsen PL. et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma?. J Hypertens 2018; 36 (02) 277-285
    CrossrefPubMedGoogle Scholar
  • 17 Bhasin S, Woodhouse L, Casaburi R. et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281 (06) E1172-E1181
    CrossrefPubMedGoogle Scholar
  • 18 Skov J, Sidelmann JJ, Bladbjerg EM, Jespersen J, Gram J. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation. Thromb Res 2014; 134 (03) 717-722
    CrossrefPubMedGoogle Scholar
  • 19 Sjøland JA, Sidelmann JJ, Brabrand M. et al. Fibrin clot structure in patients with end-stage renal disease. Thromb Haemost 2007; 98 (02) 339-345
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Carr ME, Gabriel DA. The effect of dextran 70 on the structure of plasma-derived fibrin gels. J Lab Clin Med 1980; 96 (06) 985-993
    PubMedGoogle Scholar
  • 21 Carr Jr ME, Hermans J. Size and density of fibrin fibers from turbidity. Macromolecules 1978; 11 (01) 46-50
    CrossrefPubMedGoogle Scholar
  • 22 Sidelmann J. Contact Activation of the Fibrinolytic System in Human Blood [PhD dissertation]. Odense, Denmark: University of Southern Denmark; 1997: 83
    Google Scholar
  • 23 Rijken DC, Uitte de Willige S. Inhibition of fibrinolysis by coagulation factor XIII. BioMed Res Int 2017; 2017: 1209676
    CrossrefPubMedGoogle Scholar
  • 24 Collet JP, Allali Y, Lesty C. et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
    CrossrefPubMedGoogle Scholar
  • 25 Glueck CJ, Freiberg R, Glueck HI, Tracy T, Stroop D, Wang Y. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 1995; 48 (04) 213-220
    CrossrefPubMedGoogle Scholar
  • 26 Kluft C, Preston FE, Malia RG. et al. Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults. Thromb Haemost 1984; 51 (02) 157-164
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Ledford MR, Horton A, Wang G, Brito M, Delgado L. Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation. Thromb Res 1997; 87 (05) 473-482
    CrossrefPubMedGoogle Scholar
  • 28 Small M, McArdle BM, Lowe GD, Forbes CD, Prentice CR. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Thromb Res 1982; 28 (01) 27-36
    CrossrefPubMedGoogle Scholar
  • 29 Thorisdottir H, Evans JA, Schwartz HJ, Comp P, Haluschak J, Ratnoff OD. Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. J Lab Clin Med 1992; 119 (06) 698-701
    PubMedGoogle Scholar
  • 30 Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34 (08) 513-554
    CrossrefPubMedGoogle Scholar
  • 31 Kahn NN, Sinha AK, Spungen AM, Bauman WA. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 2006; 81 (02) 95-100
    CrossrefPubMedGoogle Scholar